Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
Karuna Therapeutics, Inc. (KRTX)
Sector: Healthcare; Industry: Biotechnology

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric disorders and pain. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-04-12 Miller Andrew Craig Chief Operating Officer Sell 5,000 $114.22 $571,100 Yes
2021-03-10 Miller Andrew Craig Chief Operating Officer Sell 5,000 $118.48 $592,400 Yes
2021-03-01 Pande Atul Director Sell 2,500 $125.43 $313,575 Yes
2021-02-16 Ignelzi Troy A. Chief Financial Officer Sell 10,000 $119.57 $1,195,700 Yes
2021-02-10 Miller Andrew Craig Chief Operating Officer Sell 5,000 $114.06 $570,300 Yes
2021-02-09 PureTech Health LLC Former 10% Owner Sell 1,000,000 $118.00 $118,000,000 No
2021-02-01 Pande Atul Director Sell 2,500 $100.00 $250,000 Yes
2021-01-11 Miller Andrew Craig Chief Operating Officer Sell 5,000 $105.11 $525,550 Yes
2021-01-08 Ignelzi Troy A. Chief Financial Officer Sell 8,000 $104.49 $835,920 Yes
2020-12-14 Miller Andrew Craig Chief Operating Officer Sell 5,000 $94.82 $474,100 Yes
2020-12-14 Pande Atul Director Sell 5,714 $92.64 $529,345 Yes
2020-11-12 Miller Andrew Craig Chief Operating Officer Sell 30,000 $101.69 $3,050,749 Yes
2020-11-12 Pande Atul Director Sell 5,000 $96.84 $484,200 Yes
2020-11-10 Ignelzi Troy A. Chief Financial Officer Sell 10,000 $105.61 $1,056,054 Yes
2020-11-03 Pande Atul Director Sell 5,000 $85.00 $425,000 Yes
2020-10-12 Miller Andrew Craig Chief Operating Officer Sell 5,000 $78.67 $393,350 Yes
2020-09-16 Pande Atul Director Sell 5,000 $85.00 $425,000 Yes
2020-09-09 HEALY JAMES Director Buy 4,557 $73.75 $336,079 No
2020-09-10 Miller Andrew Craig Chief Operating Officer Sell 5,000 $75.52 $377,600 Yes
2020-09-08 Ignelzi Troy A. Chief Financial Officer Sell 2,000 $73.30 $146,600 Yes
2020-09-04 Preston Heather Director Buy 350 $72.36 $25,326 No
2020-09-08 HEALY JAMES Director Buy 62,282 $71.74 $4,467,908 No
2020-08-26 PureTech Health LLC 10%-Owner Sell 1,333,333 $76.21 $101,616,241 No
2020-08-12 Pande Atul Director Sell 5,000 $85.00 $425,000 Yes
2020-08-12 Pande Atul Director Sell 5,000 $85.00 $425,000 Yes
2020-08-12 HARRIGAN EDMUND Director Sell 10,000 $83.32 $833,200 No
2020-07-13 Pande Atul Director Sell 5,000 $95.43 $477,150 Yes
2020-07-13 HARRIGAN EDMUND Director Sell 10,000 $93.40 $934,000 No
2020-07-08 Ignelzi Troy A. Chief Financial Officer Sell 8,000 $98.74 $789,920 Yes
2020-07-01 Brannan Stephen K. Chief Medical Officer Sell 7,728 $108.53 $838,720 Yes

Insider Smart

SYSCO CORP (SYY) - PELTZ NELSON and Frank Joshua D are insiders of SYSCO CORP, check their transactions to see how they sell high and buy low. Would that be more persuasive than just buy or sell?

Insider Smart

Edesa Biotech, Inc. (EDSA) - President and CEO bought shares of EDSA in late May around $3, two weeks after their purchase, the stock jump to $9, very well timed buy.